Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Dusquetide · SGX-942, SGX945

Peptide · Modulator of sequestosome-1 (p62) ZZ domain (SQSTM1) · developed by Soligenix

Phase 3 Most advanced trial (none active)
SNGX Developer
2 Registered trials

What is Dusquetide?

Dusquetide is a synthetic five-amino-acid peptide, an innate defense regulator, that binds the ZZ domain of sequestosome-1 (p62) and activates innate immune signaling through pathways such as MAPK p38 and CCAAT-enhancer-binding protein. It is studied in oral mucositis, oral cavity and oropharyngeal squamous cell carcinoma, and Behçet disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
SGX-942, SGX945, IMX-942, SGX-94
Drug type
Peptide
Targets
sequestosome-1 (p62) ZZ domain (SQSTM1)
Mechanism
Modulator of sequestosome-1 (p62) ZZ domain (SQSTM1)
Pathways
MAPK p38 signaling, CCAAT-enhancer-binding protein signaling, innate immune regulation, cytokine expression regulation
Therapy area
Oncology
Developer
Soligenix (SNGX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
IKX7W49NLN

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03237325 Phase 3 Squamous Cell Carcinoma of the Oral Cavity and Oropharynx Completed SNGX
NCT06386744 Phase 2 Behçet Disease Completed SNGX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Behçet DiseaseOral MucositisSquamous Cell Carcinoma of the Oral Cavity and Oropharynx

More from Soligenix

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the SNGX page.

Follow SNGX, the company behind Dusquetide

See SNGX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SNGX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.